Male breast cancer accounts for 1% of all breast cancer diagnoses. Family history is a significant risk factor for male breast cancer; the relative risk of breast cancer for a female with an affected brother is approximately 30% higher than for a female with an affected sister^[@R1]^. Approximately 10% of male breast cancer cases are *BRCA2* mutation carriers while *BRCA1* mutation carriers are reported less frequently^[@R2]^. Predicated on the assumption that common variation contributes appreciably to the heritable risk of male breast cancer, and since investigation of risk alleles for breast cancer in men may provide novel insight into genetic susceptibility for the disease in females, we performed a genome-wide association study (GWAS).

Using Illumina OmniExpress arrays (Illumina, San Diego CA) we genotyped 920 male breast cancer cases ascertained from the UK (n = 805) and US (n = 115) ([Supplementary Methods](#SD1){ref-type="supplementary-material"}; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). For controls we used publicly available data on 2,912 individuals from the 1958 British Birth Cohort, genotyped on Illumina 1.2M DuoCustom arrays. After applying pre-specified quality control measures ([Supplementary Methods](#SD1){ref-type="supplementary-material"}; [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}; [Supplementary Tables 2a and 2b](#SD1){ref-type="supplementary-material"}), we estimated odds ratios (ORs) and 95% confidence intervals (CI) for 447,760 autosomal SNPs with minor allele frequencies (MAF) ≥ 5% in 823 cases and 2,795 controls. Quantile-quantile plots of *P*-values showed minimal inflation of test statistics, indicating that there was no substantial cryptic population substructure or differential genotyping between cases and controls (genomic control inflation factor λ = 1.05; [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

A total of 17 SNPs, mapping to six independent genomic regions, showed evidence of association with male breast cancer at *P* ≤ 5.0 × 10^−7^([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). We attempted to validate the most significantly associated SNP mapping to each of the six regions in 438 cases and 474 controls recruited from 12 case-control series ([Supplementary Methods](#SD1){ref-type="supplementary-material"}; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). In a combined analysis the associations of two SNPs, rs1314913 (*P* = 3.02 × 10^−13^, OR = 1.57) and rs3803662 (*P* = 3.87 × 10^−15^, OR = 1.50) attained genome-wide significance ([Table 1](#T1){ref-type="table"}; [Supplementary Tables 3 & 4](#SD1){ref-type="supplementary-material"}).

SNP rs1314913 localises to intron seven of the *RAD51B* gene (RAD51 homolog B) on chromosome 14q24.1 at 67,769,347 bp (NCBI build 36). It maps to the distal end of a linkage disequilibrium block of approximately 52 kb ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). RAD51 family members function in both mitotic and meiotic homologous recombination and in DNA double-strand break repair. rs999737, located in intron 10 of *RAD51B*, has previously been shown to be associated with risk of female breast cancer^[@R3]^. This SNP maps approximately 335 kb telomeric to rs1314913 and is separated from it by strong recombination hotspots ([Figure 1a](#F1){ref-type="fig"}; [Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). rs999737 and rs1314913 are only weakly correlated in the male breast cases (r^2^ = 0.02) and the HapMap CEU population (r^2^ = 0.006). To test formally for independence between rs1314913 and rs999737 we fitted a logistic regression model, using the discovery phase samples, adjusted for rs999737 in which the OR for rs1314913 was 1.54 (*P* = 1.04 × 10^−9^). Conversely the OR for rs999737, adjusted for rs1314913, was 0.93 (*P* = 0.25).

To provide further insight into the association at 14q24.1 we imputed genotypes in cases and controls using data from the 1,000 Genomes Project. Fifty-two imputed SNPs were more strongly associated with male breast cancer than rs1314913 and delineated an 85 kb cluster from 67.68 Mb to 67.77 Mb ([Figure 1a](#F1){ref-type="fig"}; [Supplementary Table 5](#SD1){ref-type="supplementary-material"}). To examine if any directly genotyped or imputed SNPs annotated a putative transcription factor binding site or enhancer element we conducted a bioinformatic search of the region ([Supplementary Methods](#SD1){ref-type="supplementary-material"}). Seven associated SNPs, including rs1314913, were highly evolutionarily conserved ([Supplementary Table 6](#SD1){ref-type="supplementary-material"}). Analysis of ENCODE project data, including the Broad histone modification datasets for human mammary epithelial cells (HMECs), showed that two conserved SNPs, rs1314913 and an adjacent SNP, rs1316014, were located in a transcription factor-binding site lying within a DNAse hypersensitive site flanked by regions of high H3K4 mono/di-methylation and low tri-methylation, features that are characteristic of enhancer elements ([Supplementary Figures 5 and 6](#SD1){ref-type="supplementary-material"}). *In silico* predictions are compatible with the minor alleles of both rs1314913 and rs1316014 abrogating the DNA binding sites of AP-1 and related transcription factors ([Supplementary Figure 7](#SD1){ref-type="supplementary-material"}). It is possible that the role of AP-1 in modulating estrogen signalling and transcription^[@R4]^ might explain the association between rs1314913 and male breast cancer.

We have previously shown in a much smaller study that rs3803662, a synonymous SNP in *LOC643714* mapping to chromosome 16q12.1 at 51,143,812 bp, was associated with male breast cancer risk, albeit not at genome-wide levels of significance^[@R5]^. Here we provide robust confirmatory evidence of that association ([Table 1](#T1){ref-type="table"}). Examination of imputed data suggests that the association spans a 61 kb region from 51.09 Mb to 51.16 Mb and is proximal to *LOC643174*([Figure 1b](#F1){ref-type="fig"}), localising to the gene *TOX3* (TOX high mobility group family member three).

Rare variants in two breast cancer susceptibility genes, *BRCA2* and *CHEK2*, have larger ORs in males compared with females^[@R2],[@R6]^ and we show here that this is also true for two common susceptibility alleles. Both rs1314913 and rs3083662 are striking in the magnitude of their effects. Comparing the breast cancer OR for rs3803662 in our data with the published estimate for females (OR = 1.20 \[1.16--1.24\])^[@R7]^, the effect was significantly greater in males (*P* = 7.76 × 10^−5^). Since rs1314913 is a novel breast cancer susceptibility variant there are no equivalent female estimates for comparison.

Variants at 24 loci have so far been shown to influence female breast cancer risk^[@R3],[@R7]--[@R14]^. Their associations with male breast cancer are shown in [Supplementary Table 7](#SD1){ref-type="supplementary-material"}. In addition to rs3803662, SNPs at 2q35, 6q25.1, 10q21.2, 11q13.3, 12p11.22 were significantly associated at *P*\< 0.05. Loci at 3p24.1, 9p21.3 and 14q24.1 showed borderline associations at *P* ≤ 0.1. There was no significant association, however, between variants at the *FGFR2* locus on chromosome 10q26.13 and male breast cancer risk (rs2981582; OR = 1.07 \[0.96--1.20\]; *P* = 0.21). This observation is surprising since male breast cancer is almost entirely estrogen receptor (ER) positive. rs2981582 is the SNP with the strongest known association with ER positive breast cancer in females^[@R15]^ and the power of our study to detect an allele with the same effect size as for female breast cancer at *P* ≤ 0.05 is close to 100%. rs3803662, however, is strongly associated with both ER negative and ER positive breast cancer in females^[@R15]^. Therefore the ER status of male breast cancers does not obviously explain the SNP associations.

These data provide evidence for low penetrance susceptibility to male breast cancer. Given the modest size of our study it is likely that additional risk variants can be identified by future GWAS.
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![Association and recombination plots for the 14q24.1 and 16q12.1 loci\
Directly genotyped SNPs from the discovery phase are represented as diamonds and imputed SNPs as circles. A larger diamond indicates the GWAS "hit" in each region. The strength of linkage disequilibrium between each SNP and the GWAS hit is indicated by the colour intensity of the symbol, from white (r^2^ = 0) to dark red (r^2^ = 1). Recombination rates, plotted in dark blue, are based on the HapMap CEU samples and genomic coordinates are based on NCBI build 36 of the human genome. Results are shown for the (a) 14q24.1 and (b) 16q12.1 loci. The location of rs999737 is indicated in bold at the distal end of *RAD51B* in the 14q24.1 plot.](nihms490023f1){#F1}

###### 

Summary data for the 14q21.1 SNP rs1314913 and 16q12.1 SNP rs3803662 associated with risk of male breast cancer.

  Locus                     Control MAF   Control Genotype Counts   Case MAF   Case Genotype Counts   *P*-value   OR~trend~   95% CI                                 
  ----------- ------------- ------------- ------------------------- ---------- ---------------------- ----------- ----------- -------- ----- ---------------- ------ ------------
  rs1314913                               GG                        GA         AA                                 GG          GA       AA                            
  14q24.1     GWAS          0.14          2047                      675        65                     0.21        520         261      42    4.09 × 10^−10^   1.55   1.35--1.78
  *RAD51B*    Replication   0.15          333                       117        12                     0.22        258         155      16    1.71 × 10^−04^   1.61   1.25--2.07
              Combined      0.15          2380                      782        77                     0.21        778         416      58    3.02 × 10^−13^   1.57   1.39--1.77
                                                                                                                                                                     
  rs3803662                               GG                        GA         AA                                 GG          GA       AA                            
  16q12.1     GWAS          0.26          1540                      1046       205                    0.34        356         372      95    2.51 × 10^−10^   1.46   1.30--1.64
  *TOX3*      Replication   0.27          257                       181        36                     0.37        173         204      59    2.38 × 10^−06^   1.62   1.32--1.99
              Combined      0.26          1797                      1227       241                    0.35        529         576      154   3.87 × 10^−15^   1.50   1.35--1.66
